BioMed X Institute and Merck Successfully Complete Extrachromosomal DNA in Cancer Research Project
BioMed X Institute 和默克成功完成癌症研究项目中的染色体外 DNA
- 关键词：
- 来源：
- BioMed X Institute
- 类型：
- 前沿资讯
- 语种：
- 英语
- 原文发布日期：
- 2025-02-06
- 摘要：
- BioMed X, a German independent research institute, announces the successful completion of its oncology research project in partnership with Merck. The data generated by this project has been acquired by Merck for further development, potentially leading to new therapeutic approaches in precision oncology.Launched in August 2022, the collaboration aimed to unravel the mechanisms behind the formation, propagation, and impact of ecDNA in cancer cells using state-of-the-art single-cell screening and spatial technologies. The project was led by Dr. Alexandros Drainas, winner of the BioMed X Innovation Boot Camp, and mentored by Dr. Sebastian M. Waszak, Assistant Professor at EPFL, Lausanne, Switzerland. Industry guidance provided by Dr. Balca Mardin, Head of Target Discovery & Research at Merck.The team’s research identified genes that may reduce ecDNA abundance in cancer cells. Additionally, Team EDC developed advanced spatial technologies to explore how ecDNAlocalization affects cancer cell adaptability. The project was completed earlier than expected thanks to the promising and unexpected results achieved by the team. These early findings may offer promising strategies for mitigating cancer heterogeneity and reducing the mechanisms driving therapeutic resistance, potentially improving the efficacy of existing treatments.
- 所属专题：
- 177
